Supplementary Table S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Supplementary Table S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

<p>Supplementary Table S8. Quantification of each protein-specific band normalized to vinculin (Dox-inducible RM-1-BM– and C4-2b–derived models, Fig. 3A, 3B).</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Chuandong Geng (17315310) (author)
Kolejni autorzy:	Man-Chao Zhang (17315313) (author), Ganiraju C. Manyam (17315316) (author), Jody V. Vykoukal (17315319) (author), Johannes F. Fahrmann (15052230) (author), Shan Peng (17315322) (author), Cheng Wu (17315325) (author), Sanghee Park (17315328) (author), Shakuntala Kondraganti (17315331) (author), Daoqi Wang (17315334) (author), Brian D. Robinson (16755326) (author), Massimo Loda (14958363) (author), Christopher E. Barbieri (15012150) (author), Timothy A. Yap (15028749) (author), Paul G. Corn (17315337) (author), Samir Hanash (17314360) (author), Bradley M. Broom (15022580) (author), Patrick G. Pilié (15119957) (author), Timothy C. Thompson (17315340) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling DNA Damage and Repair Drug Mechanisms Genitourinary Cancers Prostate cancer Small Molecule Agents
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S21 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
od: Chuandong Geng (17315310)
Wydane: (2025)

Supplementary Data S8 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
od: Naoual Menssouri (16617248)
Wydane: (2025)

Image 8_Optimised dissociation and multimodal profiling of prostate cancer stroma reveal fibromuscular cell heterogeneity with clinical correlates.tiff
od: Elisabeth Damisch (22679276)
Wydane: (2025)

<b>Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025: A Podcast</b>
od: Adis Journals on behalf of: (10953492)
Wydane: (2025)

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Wydane: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Wydane: (2025)

Figure 2 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Wydane: (2025)

Figure 3 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
od: Martin Sjöström (14845882)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_rirqafet4b8r52v8k2s7rpicja